Want to join the conversation?
$CELG announced interim topline data from trial of investigational oral GED-0301 in patients with active Crohn's disease. Crohn's disease is an immune-mediated, chronic inflammatory condition of the gastrointestinal tract. The primary objective of the study is to explore the effect of GED-0301 on endoscopic outcomes.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.